NCT06873854View on ClinicalTrials.gov

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 26, 2025

Primary Completion Date

January 26, 2028

Study Completion Date

January 26, 2030

Conditions
Advanced Solid Tumor
Interventions
DRUG

LM-108

Q3W, Intravenous Drip

DRUG

Toripalimab

Q3W, Intravenous Drip

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

LaNova Medicines Limited

INDUSTRY